Sep 28, 2026

Featuring perspectives from Dr Samuel J Klempner and Dr Stephen "Fred" Divers, moderated by Dr Divers, including the following topics:

• Introduction (0:00)
• First-Line Treatment of Metastatic Gastroesophageal Cancer (1:48)
• Management of HER2-Positive Gastroesophageal Cancer (25:11)
• Neoadjuvant Therapy for Gastroesophageal Cancer (45:13)

Note to listeners: Subsequent to the recording of this symposium, the FDA approved zanidatamab in combination with chemotherapy with and without tislelizumab for HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma based on results from the Phase III HERIZON-GEA-01 trial.

CME information and select publications